## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract, without access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors propose that six flavonoids structurally similar to curcumin, namely apigenin, isoliquiritigenin, liquiritigenin, luteolin, methylophiopogonanone A (MPA), and methylophiopogonanone B (MPB), can stabilize the p53Y220C DNA binding domain and restore its tumor suppressor function. This is supported by molecular docking, molecular dynamics (MD) simulations, and cytotoxicity assays in the BxPC-3 pancreatic cancer cell line. The authors specifically highlight MPA and MPB as showing 75% cell death at 100 microM concentration and suggest therapeutic potential for combinatorial therapy.
- **Visible evidence base** Abstract text only; no methodological details, numerical results, statistical analyses, or experimental protocols are provided
- **Missing materials affecting confidence** Full manuscript, methods section, docking scores, MD simulation parameters and trajectories, secondary structure analysis data, cytotoxicity assay details (including controls, replicates, and statistical treatment), and any structural or functional validation data

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting hypothesis that flavonoids could act as reactivators of the p53Y220C mutant, building on prior work with curcumin. However, the evidence as described is insufficient to establish the central claims. The computational results are only qualitatively summarized, and the cell-based data lack critical context such as controls, dose-response relationships, and statistical significance. The conclusion that MPA and MPB have therapeutic potential is premature given the limited evidence presented.
- **Who would be interested in the results, and why** Researchers in cancer biology, particularly those focused on p53 mutations and targeted therapies, as well as computational chemists interested in small molecule-protein interactions. The potential for natural compounds to restore mutant p53 function is of broad interest to drug discovery and structural biology communities.
- **Major strengths** The study addresses a clinically relevant problem, namely the Y220C mutation, which is a well-known structural mutant of p53. The use of multiple computational and experimental approaches is commendable. The focus on flavonoids, which are natural compounds with known bioactivity, provides a plausible starting point for therapeutic development.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract lacks quantitative evidence from docking and MD simulations, such as binding energies, RMSD values, or stability metrics. The cytotoxicity data are presented without reference to controls, such as wild-type p53 cell lines or untreated cells, and without statistical analysis. The claim of "restoration to wild type" is not supported by functional assays, such as transcriptional activity or downstream target gene expression.
- **Assessment against Nature-style criteria** 
  - Originality: Moderate. The concept of reactivating mutant p53 is not new, and the use of curcumin analogues is a logical extension of prior work, but the specific flavonoids tested may offer some novelty.
  - Scientific importance: High, given the prevalence of p53 mutations in cancer and the need for targeted therapies.
  - Interdisciplinary readership: The topic bridges computational biology, structural biology, and oncology, which could appeal to a broad audience, but the abstract does not provide enough detail to engage specialists in each field.
  - Technical soundness: Not assessable from the abstract alone. The lack of methodological detail and quantitative results prevents evaluation of the rigor of the computational and experimental approaches.
  - Readability for nonspecialists: The abstract is generally clear, but terms like "structural crevice" and "secondary structure analysis" may require some background knowledge. The flow is logical, but the conclusions are overstated relative to the evidence.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a promising direction, but the claims require substantial additional data and clarification to be convincing.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The authors claim that "secondary structure analysis after the MD simulations suggested that these compounds could stabilize the mutant p53 DNA binding domain to the wild type."
- **Evidence pointer** Abstract text, location not provided
- **Concern** The claim of stabilization to the wild type is based on an unspecified "secondary structure analysis" with no quantitative metrics, such as RMSD, RMSF, or secondary structure content percentages. No comparison to the wild-type p53 under the same conditions is described.
- **Why it matters** Without quantitative data and a direct comparison to wild-type p53, the assertion that the compounds restore the mutant to a wild-type-like state is unsupported. This is a central claim of the study and cannot be evaluated from the abstract.
- **Resolution test** Provide specific MD simulation metrics, such as time-averaged RMSD values, per-residue fluctuations, and secondary structure assignments, with statistical comparisons between apo mutant, mutant with each compound, and wild-type p53.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Experimental rigor
- **Claim pointer** The authors state that "the compounds MPA and MPB showed 75% cell death at 100 microM concentration" in BxPC-3 cells.
- **Evidence pointer** Abstract text, location not provided
- **Concern** The cytotoxicity data are presented as a single percentage without mention of controls, such as untreated cells, vehicle-treated cells, or a positive control like curcumin. No dose-response curve, replicate numbers, or statistical analysis are provided. The specificity of the effect to p53Y220C is not established, as no comparison to a p53 wild-type cell line or a p53-null cell line is mentioned.
- **Why it matters** Cell death at a single concentration could be due to general toxicity rather than p53-specific reactivation. Without appropriate controls and statistical validation, the therapeutic potential of MPA and MPB cannot be assessed.
- **Resolution test** Include full dose-response curves, IC50 values, statistical tests (e.g., ANOVA with post-hoc comparisons), and experiments in control cell lines to demonstrate p53-dependent effects.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim scope
- **Claim pointer** The authors propose that "flavonoids MPA and MPB have the therapeutic potential to restore p53Y220C and could be used as a combinatorial therapy to reduce the dosage burden."
- **Evidence pointer** Abstract text, location not provided
- **Concern** The conclusion of therapeutic potential is extrapolated from in silico and in vitro data only. No in vivo studies, pharmacokinetic data, or evidence of functional restoration of p53 transcriptional activity are provided. The suggestion of combinatorial therapy is speculative without data on synergy with existing drugs.
- **Why it matters** Therapeutic claims require evidence of efficacy and safety in relevant models. The current evidence is too preliminary to support such a strong conclusion.
- **Resolution test** Provide functional assays, such as p53 reporter gene activity or downstream target expression, and ideally in vivo efficacy data or at least a clear rationale for combinatorial use based on mechanistic studies.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Introduction of compounds
- **Evidence pointer** Abstract text, location not provided
- **Issue** The abstract lists six flavonoids but does not specify which ones were used in the cell-based assays beyond MPA and MPB. It is unclear if all six were tested in cells or only a subset.
- **Required correction** Clarify which compounds were tested in each assay and whether the 75% cell death was specific to MPA and MPB or observed for others as well.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Methodological detail
- **Affected element** Docking and MD simulation methods
- **Evidence pointer** Abstract text, location not provided
- **Issue** The abstract does not describe the docking software, scoring functions, force fields, or simulation times used. This limits reproducibility and assessment of methodological rigor.
- **Required correction** Include brief methodological details in the abstract or refer to a methods section with full parameters.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Interpretation
- **Affected element** Comparison to curcumin
- **Evidence pointer** Abstract text, location not provided
- **Issue** The study is framed as an extension of prior work with curcumin, but no direct comparison of the flavonoids to curcumin in the same assays is presented. This weakens the rationale for why these compounds are superior or complementary.
- **Required correction** Include a comparative analysis with curcumin under identical conditions to support the claim of improved or equivalent efficacy.

## Risk / unsupported claims
- The claim that the compounds "stabilize the mutant p53 DNA binding domain to the wild type" is unsupported without quantitative structural data and direct wild-type comparison.
- The claim of "therapeutic potential" for MPA and MPB is unsupported by the evidence presented, which lacks in vivo or functional validation.
- The suggestion of "combinatorial therapy to reduce the dosage burden" is speculative and not backed by any data on drug interactions or dosing.
- The general efficacy of all six flavonoids is not established, as only MPA and MPB are mentioned in the cell-based results.